Atossa (ATOS) Given 180-Day Nasdaq Extension; Compliance Deadline Feb 17, 2026

Rhea-AI Filing Summary

Atossa Therapeutics, Inc. notified Nasdaq that it was not in compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid of $1.00 for 30 consecutive business days. The company's initial compliance period ended on August 20, 2025, and after requesting an extension, Nasdaq granted a 180-day extension on August 21, 2025, moving the deadline to regain compliance to February 17, 2026.

Positive

• Nasdaq granted a 180-day extension to regain compliance, extending the cure deadline to February 17, 2026.

Negative

• Company was found non-compliant with Nasdaq Listing Rule 5550(a)(2) because the common stock did not maintain a $1.00 closing bid for 30 consecutive business days.
• Initial compliance period expired on August 20, 2025, requiring the company to seek an extension to avoid immediate delisting.

Insights

Financial Analyst

TL;DR: Nasdaq found ATOS non-compliant with the $1.00 minimum bid rule; a 180-day cure period was granted to regain compliance.

The filing discloses a listing deficiency under Nasdaq Listing Rule 5550(a)(2) due solely to the security's failure to maintain a $1.00 closing bid for the required 30 consecutive business days. The company exhausted its initial compliance period on August 20, 2025, and received a formal 180-day extension on August 21, 2025, establishing a new compliance deadline of February 17, 2026. This is a procedural, time-bound remedy that allows the issuer to avoid immediate delisting if it meets the stated price condition within the extension period.

Corporate Governance Expert

TL;DR: The company faces a governance-related listing deficiency but has been granted additional time to cure the deficiency.

The disclosure is focused on a specific Nasdaq listing rule violation tied to market price rather than governance actions or disclosures. The extension indicates Nasdaq is providing the company a remediation window rather than initiating delisting proceedings at this time. The filing does not include remediation steps, share changes, or other corporate actions; it only records the non-compliance finding and the extended deadline of February 17, 2026.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What rule did Atossa Therapeutics (ATOS) fail to comply with?

The company failed to comply with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement of $1.00 per share.

Why was ATOS found non-compliant with Nasdaq?

Because its common stock failed to maintain a minimum closing bid of $1.00 per share for 30 consecutive business days.

When did the company's initial compliance period end?

The initial compliance period ended on August 20, 2025.

Was an extension granted and what is the new deadline?

Yes. Nasdaq granted a 180-day extension on August 21, 2025, setting the new deadline to regain compliance at February 17, 2026.

Does the filing state any remediation steps taken by ATOS?

The provided content does not state any specific remediation steps taken by the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/21/2025 - 04:05 PM Learn about SEC filing dates

0001488039false00014880392025-08-212025-08-21

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 21, 2025

Atossa Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-35610	26-4753208
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
10202 5th Avenue NE, Suite 200
Seattle, Washington				98125
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 588-0256

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.18 par value		ATOS		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On February 21, 2025, Atossa Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq, because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company’s initial compliance period ended on August 20, 2025, and the Company subsequently requested an extension. On August 21, 2025, the Company was informed that its deadline to regain compliance was extended by 180 days, or until February 17, 2026

The Notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq. The Company intends to actively monitor the bid price for its common stock, and is committed to considering available options to regain compliance with the minimum bid price requirement, including, if necessary, potentially effectuating a reverse stock split.

* * *

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Atossa Therapeutics, Inc.
Date:	August 21, 2025	By:	/s/ Heather Rees
			Heather Rees Chief Financial Officer